UB Paderborn / Katalog / Suche / in CDI

Es ist ein Fehler in der Kommunikation mit einem externen System aufgetreten. Bitte versuchen Sie Ihre letzte Aktion erneut. Sollte der Fehler bestehen bleiben, setzen Sie sich bitte mit dem Informationszentrum der Bibliothek in Verbindung oder versuchen Sie es später erneut.

1 – 25 von 66

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Therapeutic Potential of Lipoprotein(a) Inhibitors

Drugs (New York, N.Y.), 2024-06, Vol.84 (6), p.637-643

Nicholls, Stephen J.

2024

Volltextzugriff (PDF)

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

Cardiovascular diabetology, 2021-01, Vol.20 (1), p.13-13, Article 13

2021

Volltextzugriff (PDF)

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program

Cardiovascular diabetology, 2024-02, Vol.23 (1), p.63-63, Article 63

2024

Volltextzugriff (PDF)

Characterization of plaque phenotypes exhibiting an elevated pericoronary adipose tissue attenuation: insights from the REASSURE-NIRS registry

The international journal of cardiovascular imaging, 2023-10, Vol.39 (10), p.1943-1952

2023

Volltextzugriff (PDF)

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2016-02, Vol.16 (1), p.55-65

2016

Volltextzugriff (PDF)

Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes

Cardiovascular diabetology, 2022-08, Vol.21 (1), p.1-163, Article 163

2022

Volltextzugriff (PDF)

High-density lipoproteins attenuate high glucose-impaired endothelial cell signaling and functions: potential implications for improved vascular repair in diabetes

Cardiovascular diabetology, 2017-09, Vol.16 (1), p.121-121, Article 121

2017

Volltextzugriff (PDF)

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial

Cardiovascular diabetology, 2021-06, Vol.20 (1), p.125-125, Article 125

2021

Volltextzugriff (PDF)

Clinical predictors and sequelae of computed tomography defined leaflet thrombosis following transcatheter aortic valve replacement at medium-term follow-up

Heart and vessels, 2021-09, Vol.36 (9), p.1374-1383

2021

Volltextzugriff (PDF)

Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study

Cardio-oncology (London, England), 2022-12, Vol.8 (1), p.23-23, Article 23

2022

Volltextzugriff (PDF)

ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies

Cardiovascular drugs and therapy, 2012-04, Vol.26 (2), p.181-187

2012

Volltextzugriff (PDF)

How Will Our Practice Change After the CLEAR Outcomes Trial?

Current atherosclerosis reports, 2024-03, Vol.26 (3), p.83-89

2024

Volltextzugriff (PDF)

The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors

Current cardiology reports, 2019-04, Vol.21 (4), p.18-18, Article 18

Nicholls, Stephen J.

2019

Volltextzugriff (PDF)

CETP Inhibitors: Should We Continue to Pursue This Pathway?

Current atherosclerosis reports, 2022-12, Vol.24 (12), p.915-923

2022

Volltextzugriff (PDF)

Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications

Cardiovascular drugs and therapy, 2022-04, Vol.36 (2), p.347-362

2022

Volltextzugriff (PDF)

The Riskier Lipid: What Is on the HORIZON for Lipoprotein (a) and Should There Be Lp(a) Screening for All?

Current cardiology reports, 2021-08, Vol.23 (8), p.97-97, Article 97

2021

Volltextzugriff (PDF)

Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2018-04, Vol.18 (2), p.109-115

2018

Volltextzugriff (PDF)

Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation

PharmacoEconomics, 2022-11, Vol.40 (11), p.1033-1042

2022

Volltextzugriff (PDF)

The mitral to aortic/pulmonary velocity-time integral ratio is a simple, feasible and accurate discriminator for echocardiographic evaluation of severe isolated mitral regurgitation

The international journal of cardiovascular imaging, 2024-10

2024

Volltextzugriff (PDF)

Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2019-04, Vol.19 (2), p.113-131

2019

Volltextzugriff (PDF)

Elevated HDL-bound miR-181c-5p level is associated with diabetic vascular complications in Australian Aboriginal people

Diabetologia, 2021-06, Vol.64 (6), p.1402-1411

2021

Volltextzugriff (PDF)

Myocardial extracellular volume measurement using cardiac computed tomography

The international journal of cardiovascular imaging, 2024-10

2024

Volltextzugriff (PDF)

Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2019-08, Vol.19 (4), p.343-348

2019

Volltextzugriff (PDF)

Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study

Cardiovascular drugs and therapy, 2022-12, Vol.36 (6), p.1175-1186

2022

Volltextzugriff (PDF)

High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2020-02, Vol.20 (1), p.11-18

2020

Volltextzugriff (PDF)

1 – 25 von 66

Suche als RSS-Feed

Aktive Filter

KollektionSpringer Nature - Complete Springer Journals

Nur zeigenMit Volltextzugriff

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)

Publikationsform

Artikel
(66)

Sprache

Englisch
(66)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(59)
Science & Technology
(59)
Cardiovascular System & Cardiology
(41)
Humans
(41)
Medicine
(39)
Medicine & Public Health
(39)
Cardiac & Cardiovascular Systems
(36)
Cardiology
(33)
Atherosclerosis
(26)
Cardiovascular Disease
(17)
Risk Factors
(17)
Lipids
(16)
Pharmacology & Pharmacy
(16)
Male
(14)
Cardiovascular Diseases - Prevention & Control
(13)
Cholesterol
(13)
Clinical Trials
(13)
Female
(13)
Animals
(12)
Diabetes
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Therapeutic Potential of Lipoprotein(a) Inhibitors

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program

Characterization of plaque phenotypes exhibiting an elevated pericoronary adipose tissue attenuation: insights from the REASSURE-NIRS registry

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial

Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes

High-density lipoproteins attenuate high glucose-impaired endothelial cell signaling and functions: potential implications for improved vascular repair in diabetes

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial

Clinical predictors and sequelae of computed tomography defined leaflet thrombosis following transcatheter aortic valve replacement at medium-term follow-up

Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study

ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies

How Will Our Practice Change After the CLEAR Outcomes Trial?

The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors

CETP Inhibitors: Should We Continue to Pursue This Pathway?

Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications

The Riskier Lipid: What Is on the HORIZON for Lipoprotein (a) and Should There Be Lp(a) Screening for All?

Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease

Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation

The mitral to aortic/pulmonary velocity-time integral ratio is a simple, feasible and accurate discriminator for echocardiographic evaluation of severe isolated mitral regurgitation

Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs

Elevated HDL-bound miR-181c-5p level is associated with diabetic vascular complications in Australian Aboriginal people

Myocardial extracellular volume measurement using cardiac computed tomography

Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial

Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study

High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?

Aktive Filter

Suchergebnisse filtern